The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with renal cell carcinoma was developed by the Society for Immunotherapy of Cancer (SITC) and published online by the Journal for ImmunoTherapy of Cancer, in 2016.This consensus statement provides expert evidence-based recommendations for the use of cytokine-based immunotherapies, IL-2 and IFN, and the more recently approved drug, nivolumab, a checkpoint inhibitor. This statement includes recommendations for patient selection, toxicity management, clinical end points, and sequencing or combination of therapies.
Published Nov. 15, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma."
Key points from SITC's Cancer Immunotherapy Guidelines Renal Cell Carcinoma have been distilled into Pocket Guide. This condensed, easily accessible version of the full Cancer Immunotherapy Guideline is a quick-reference tool available in both digital and print.Download SITC's Cancer Immunotherapy Guidelines Renal Cell Carcinoma Pocket Guide on any desktop or mobile device today.*
*Available only through the Guideline Central App.
ORDER Digital/Print Guide
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com